Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 4/20 | 0.35 |
| ▸ | SI | P14410 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396589 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL17976723 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL10026372 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL15468191 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL14356304 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL7150041 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL7644266 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL17972475 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL7152288 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 | |
| SCHEMBL1389565 | 1.00 | LGALS8 (0.40) | LGALS8ALDH1A1TSHRLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| EP-2404926-B1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN LTD (TW) | 2014-08-20 | — | — | EP | disclosed |
| EP-2404926-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-adenine | ScinoPharm Taiwan, Ltd. (TW) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | LGALS8 1201/4885ALDH1A1 996/4885TSHR 2261/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | LGALS8 1931/4885ALDH1A1 1819/4885TSHR 3619/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | LGALS8 487/4885ALDH1A1 1897/4885TSHR 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.